Definition

An alternating, 2-vector replicating arenaviral combination agent composed of two genetically engineered replicating vectors: HB-301, which is based on the arenavirus lymphocytic choriomeningitis virus (LCMV), and HB-302, which is based on the arenavirus Pichinde virus (PICV), and both expressing the same transgenes encoding for the two prostate cancer-associated antigens prostatic acid phosphatase (PAP) and prostate specific antigen (PSA), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the PAP/PSA-expressing arenaviral vectors HB-302/HB-301 express PSA and PAP peptides and cause antibody-mediated and cytotoxic T-lymphocyte (CTL)-mediated immune responses against prostate cancer cells expressing PSA and PAP.